Bergapten
产品说明书
 |
同义名 : | 佛手苷内酯 ;5-Methoxypsoralen; 5-MOP; NSC 95437; Heraclin |
| CAS号 : | 484-20-8 | |
| 货号 : | A141454 | |
| 分子式 : | C12H8O4 | |
| 纯度 : | 98% | |
| 分子量 : | 216.19 | |
| MDL号 : | MFCD00010272 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | 5-Methoxypsoralen (Bergapten) is a natural anti-inflammatory and anti-tumor agent isolated from bergamot essential oil, other citrus essential oils and grapefruit juice. 5-methoxypsoralen led to time-dependent as well as dose-dependent inhibitory effects on U-87MG human glioma cells. 5-Methoxypsoralen led to a substantial decrease of cell count along with distorted cell morphology. 5-methoxypsoralen also led to dose-dependent G2/M phase cell cycle arrest. 5-Methoxypsoralen-treated cells also exhibited altered cell ultrastructure with the appearance of autophagic vacuoles and the number of these vacuoles increased with increasing drug dose[3]. 5-MOP (5-Methoxypsoralen) increased the activity of NAT (N-acetyltransferase) and also increased the further metabolism of AAF ( 2-acetylaminofluorene) at 24 h in the rat stomach. 5-MOP decreased the activity of NAT only at 72-h incubation in SC-M1 cells. The optimal concentrations of 5-MOP to induce decreased NAT activity in SC-M1 (human stomach) cells were 0.05 mM to 25 mM. In COLO 205 cells, there is decreased NAT activity at low doses of Bergapten (0.05 mM and 0.5 mM) and increased NAT activity at a high dose (50 mM)[4]. In addition, DSG (diosgenin) and 5-MOP may improve insulin resistance through an ER-mediated PI3K/Akt activation pathway[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00533195 | Atopic Dermatitis | Phase 3 | Completed | - | Austria ... 展开 >> Medical University of Vienna; University Clinic of Dermatology; Division of Special and Environmental Dermatology Vienna, Austria, 1090 收起 << |
| NCT00811005 | Pustular Palmoplantar Psoriasi... 展开 >>s 收起 << | Phase 3 | Unknown | October 2010 | Austria ... 展开 >> Medical University of Vienna; University Clinic of Dermatology; Division of Special and Environmental Dermatology Vienna, Austria, 1180 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.63mL 0.93mL 0.46mL |
23.13mL 4.63mL 2.31mL |
46.26mL 9.25mL 4.63mL |
| 参考文献 |
|---|